Brief: Benitec Biopharma Receives FDA Clearance Of IND For BB-301
26/06/2023 13:38
June 26 (Reuters) - Benitec Biopharma Inc BNTC.O :
* BENITEC BIOPHARMA RECEIVES FDA CLEARANCE OF THE IND FOR
BB-301
FOR THE TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY
* BENITEC BIOPHARMA- INTERIM SAFETY, EFFICACY DATA TO BE
AVAILABLE
FROM BB-301 PHASE 1B/2A STUDY ABOUT EVERY 90 DAYS FOLLOWING
DOSING OF EACH SUBJECT
Source text for Eikon: ID:nGNX5wJsGH
Further company coverage: BNTC.O
((Reuters.Briefs@thomsonreuters.com;))